MedPath

A study of two drugs Amritvalli-Ghrit and Aragvadhadi-ghrit after Therapeutic Emesis in Ek-Kustha (Psoriasis)

Phase 2
Conditions
Health Condition 1: L400- Psoriasis vulgaris
Registration Number
CTRI/2023/05/052220
Lead Sponsor
ATIONAL INSTITUTE OF AYURVEDA
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Patients willing for trial.

2.Clinically diagnosed and confirmed cases of Psoriasis

Exclusion Criteria

1.Patients with age below 18 and above 60 yrs.

2.Pregnant women and lactating mothers.

3.Patients suffering from serious systemic disorders like Diabetes Mellitus, Cardiac and

Renal Disorders, Malignant disease, Major liver disorders etc.

4.Patients having complication of Psoriasis like Psoriatic Arthropathy, erythrodermic psoriasis etc.

5.Patients Contraindicated for vamana karma as per classical Ä?yurveda texts.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To see the changes in the PASI Score and the other Subjective parameters grading score.Timepoint: 2 weeks, 4 weeks and 8 weeks <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
Changes in the objective parameters of disease. <br/ ><br>Timepoint: 2 weeks, 4 weeks and 8 weeks
© Copyright 2025. All Rights Reserved by MedPath